Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Primary Outcome Measures Efficacy [ Time Frame: 6 weeks (Arm B) or 8 weeks (Arm C) ] The fraction of evaluable patients who experience a PR or CR will be determined and this fraction will be reported along with an 80% and 95% confidence interval. Secondary Outcome Measures Safety [ Time Frame: 21 days (Arm B) or 28 days (Arm C) ] Safety ... [More >>]

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)

Primary Outcome Measures Safety [ Time Frame: up to 90 days after end of study treatment ] The proportion of patients experiencing treatment-related grade 3-4 adverse events (AEs) according to NCI-CTCAE criteria, version 4.0. PD-L1 expression induction by the treatment [ Time Frame: up to 24 months ] Proportion of patients showing PD-L1 expression ... [More >>]

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 12 months ] TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Secondary Outcome Measures Cmax of INCAGN02385 [ Time Frame: Up to 12 months ] Maximum observed ... [More >>]

Olaparib in People With Malignant Mesothelioma

Primary Outcome Measures Objective response rate [ Time Frame: 6 months after enrollment of last patient ] Percentage of subjects overall who experienced partial or complete response. Percentage of subjects with germline DNA repair mutation who experienced partial or complete response. Percentage of subjects with BAP1 somatic mutations who experienced partial or ... [More >>]

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Primary Outcome Measures Progression-free survival (PFS) [ Time Frame: Approximately 13 months ] Defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to ... [More >>]

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Primary Outcome Measures Response Rate [ Time Frame: 24 months ] Evaluate response rate [complete response (CR) + partial response (PR)] of nivolumab in combination with ramucirumab in subjects with previously-treated mesothelioma. Response assessment will be performed using modified RECIST 1.1 criteria. Secondary Outcome Measures Adverse event assessment [ Time Frame: 24 months ] Assess ... [More >>]

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Primary Outcome Measures Incidence of DLTs (dose-limiting toxicity) [ Time Frame: 6 weeks (42 days) ] Eligibility Inclusion Criteria Signed informed consent Male or female subjects ≥ 18 years of age ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1 Subjects with advanced, histologically or cytologically confirmed epithelioid mesothelioma (pleural or peritoneal) or serous ... [More >>]

Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer (STEP PC)

Primary Outcome Measures Establish that stepped PC is non-inferior to early integrated PC in improving patients' QOL, as measured by the FACT-L [ Time Frame: 24 Weeks ] Quality of life as measured by the Functional Assessment of Cancer Therapy-Lung Secondary Outcome Measures Assess whether stepped PC is non-inferior to early integrated PC with ... [More >>]

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Primary Outcome Measures Safety and tolerability [ Time Frame: 4 months after last patient has enrolled ] Reporting of adverse events with grade 3 and grade 4 fraction at each dose level Maximum tolerated dose [ Time Frame: 21 days after the last patient in the dose escalation cohort has initiated study theapy ... [More >>]

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. (MesoTRAP)

Primary Outcome Measures To measure the standard deviation of Visual Analogue Scale scores for breathlessness [ Time Frame: Daily from randomisation to 12 months ] The Visual Analogue Scale (VAS) is a 100mm line for patients to record the severity of a their breathlessness where 0mm is "No breathlessness at all" and ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.